• About Us
  • News
  • Publications
  • Events
  • Careers
  • Contact
ProMabLogoProMabLogoProMabLogoProMabLogo
  • Login
  • 0 Items ($0.00)
    My Cart 1
  • Login
  • 0 Items ($0.00)
    My Cart 1
  • Top Sellers
    • CD19scFv-BEAM-CD28-CD3ZCD19scFv-BEAM-CD28-CD3ζ
    • CAR-T_Cell_MediumCAR-T Cell Medium
    • CD28-CD3_PM-T-Cell_Activation__Expansion_Beads_editCD28-CD3 Activation Beads
    • Cancer._Stem_PremiumCancer Stem Premium
    • P16_Antibody-v2P16 Antibody
  • Products
    • COVID19_8-04-2020COVID-19
    • primary-antibodyPrimary Antibody
      • Polyclonal Antibodies
      • Monoclonal Antibodies
    • Protein_IconFull-Length Protein
      • Recombinant Proteins
      • Natural Proteins
      • COVID-19 Research Products
    • CAR-T_iconCAR-T/CAR- NK
      • CAR-T cells
      • CAR-NK cells
      • T cell Activation Beads
      • Peripheral Blood Monocytes
    • Hempotological_products_IconHematological Products
      • Primary Cells
      • Non-Transduced T cells
      • Cell Media
      • Freezing Media
    • Icon_Product_mRNP_Lipid Nanoparticle_5_02_2022_finalmRNA-Lipid Nanoparticles
      • mRNA Products
      • LNP Products
    • stem-cell-iconCancer Stem Cells
      • Cancer Stem Cell Media
      • Hepatocellular Carcinoma (HCC)
      • Kidney Cancer
      • Ovarian Adenocarcinoma
      • Pancreatic Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
      • Lung Cancer Non-Small Cell (NSCLC)
      • Bladder Cancer
      • Breast Carcinoma
      • Colorectal Cancer
      • Glioblastoma
      • Head and Neck (H&N) Carcinoma
  • Services
    • v1-_Licensing_and_Distributing_CAR_Technology_7_22_2019_edit-1Licensing and Distributing CAR Technology
    • No_circles_-v2_Engineered_Cell_Lines-7_22_2019_finalCAR-T/CAR-NK Development
      • Custom CAR-T Cell Development
      • Custom CAR-NK Cell Development
      • Custom CAR-Macrophage Cell Development
      • Custom Gamma Delta T Cell Development
      • mRNA-LNP Gene Delivery
      • Lentivirus Production
      • Animal Research
      • Cancer Stem Cell Services
    • Cell_Based_Assay1_lastCell Based Assays
      • Flow Cytometry Services –
      • T Cell Specificity Assay
      • T Cell Activation & Proliferation Assay
      • Responsive T Cell Trafficking Assay
      • Cytokine Response Assay
      • Macrophage Polarization Assay
      • DC Migration Assay
    • Icon_ Services_mRNP_Lipid Nanoparticle_5_02_2022_finalmRNA-Lipid Nanoparticles
      • mRNA-LNP Gene Delivery
    • No_circles_-v3-Custom_Antibody_Engineering_7_22_2019_finalAntibody Engineering Services
      • Mouse Monoclonal Antibodies
      • Rabbit Monoclonal Antibodies
      • Human Monoclonal Antibodies
      • Recombinant Antibodies
      • Bispecific Antibodies
      • Antibody Humanization
      • Rabbit Polyclonal Antibodies
      • Hybridoma Sequencing
      • Antibody Production
    • No_circles_-v4-Protein_Expression_Services_7_22_2019_finalProtein Expression Services
      • E.coli Expression
      • Baculovirus Expression
      • Mammalian Expression
      • Stable Cell Line Development
      • Peptide Synthesis
      • Gene Synthesis Services
  • Protocols & Troubleshooting
    • Protocols
    • Technology
    • Troubleshooting
    • FAQ
Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA
February 25, 2020
ProMab CAR-T Webinar
October 21, 2020

ProMab Presents Promising Results in Humanized CD19 CAR-T Cells Trial

Quick Facts

ProMab’s humanized CD19 CAR-T platform is a CAR T-cell therapy approved for adults with treatment of relapsed and refractory hematological tumors. By empowering an individual’s immune system to recognize and destroy cancer cells, CAR-T cell therapy can give the individual a fighting chance when cancer returns or resists other treatments. “In our clinical study of 10 patients with hematological tumors who had experienced other treatment failures, ProMab helped 70% [7 out of 10] of patients achieve complete remission,” said John Wu, President and CEO of ProMab. “We are aiming to provide patients with alternative means to treat their hematological tumors and save more lives. ProMab’s CAR-T/NK cell technology platforms can meet that goal. Our study with humanized CD19 CAR-T cells for the treatment of relapsed and refractory hematological tumors have demonstrated hope for patients and the future of CAR-T technology,” added John Wu.

Check our press release to learn more:

https://www.businesswire.com/news/home/20200727005246/en/ProMab-Presents-Promising-Results-Humanized-CD19-CAR-T

Share

Sign up for news & promotions:

Products

  • Antibodies
  • Proteins
  • CAR T/NK Cells
  • Cell Lines
  • Cell Culture

Services

  • CAR-T/CAR-NK Development
  • Custom Antibodies
  • Synthesis and Expression
  • Clinical Research

Resources

  • Protocols
  • Technology
  • Troubleshooting
  • FAQ

Promab Biotechnologies

  • Promotions
  • About
  • News
  • Publications
  • Careers
  • Contact Us
Copyright © ProMab 2022 All Rights Reserved ProMab Biotechnologies, Inc. | 2600 Hilltop Drive, Building B, Suite C320, Richmond, CA 94806 USA | Email: info@promab.com